Abstract library

13 results for "Peeters".
#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Marianne Pavel
#490 Effect of Open-Label Everolimus After Disease Progression in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
Introduction: In the RADIANT-2 study (NCT00412061), Everolimus + Octreotide LAR (E+O) resulted in a clinically meaningful increase in median progression-free survival (PFS; by adjudicated central review) of 5.1 months v. placebo + Octreotide LAR (P+O) in patients with advanced NET with a history of carcinoid syndrome. Investigator-assessed PFS was 12.0 months for E+O compared with 8.6 months for P+O, respectively. On radiologically confirmed disease progression, P+O patients could cross over to open-label E+O.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dieter Hörsch
Authors: Hörsch D, Luppi G, Jehl V, Peeters M, ...
#775 Whole Exome Sequence Of BON-1 And QGP-1, Two Human Pancreatic Neuroendocrine Tumor Cell Lines, Reveals Homozygous Loss Of Function Mutations In TP53, HRNR and CYFIP2.
Introduction: The human BON-1 and QGP-1 cell lines are two models often used in pancreatic neuroendocrine tumor (PNET) research. Data on protein-changing mutations in these cell lines is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Timon Vandamme
#977 Inducing, Understanding and Overcoming Resistance to Everolimus in Pancreatic Neuroendocrine Tumors
Introduction: Treatment with the mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumors (PNETs). However, adaptive resistance to mTOR inhibition is described.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Timon Vandamme
Keywords: everolimus
#1235 The Belgian DNET Registry: A Prospective, National, Web-Based Registry of Digestive Neuro-Endocrine Tumours (NET). Status After 2 Years of Inclusion.
Introduction: NET are rare neoplasms. The Belgian Group of Digestive Oncology created a web-based registry to have an overview on incidence, diagnosis and therapies performed in Belgian pts. The DNET registry was launched in 01/2012.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath
Keywords: Registry, Belgium
#1461 Whole Exome Sequencing of Three Families with Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (siNETs) are the most prevalent small intestine neoplasms. However, familial siNETs are rarely described.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Matthias Beyens
#1543 Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?
Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: drs. Kimberly Kamp
Keywords: GEP-NET, CgA, prognosis
#1895 Prospective Study on the Impact of a Multi-Institutional NET-Specific Multidisciplinary Tumor Board on Individual Treatment Plans
Introduction: A multi-institutional health network (nine hospitals) was set up in the Belgian Antwerp-Waasland region for the multidisciplinary care of gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients, called “NETwerk”. Local multidisciplinary teams refer all GEP-NET patients to be discussed among specialists, experienced in NET diagnostics and treatment, at a NET specific multidisciplinary tumorboard (MDT).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Marc Peeters
#1896 Launching NETwerk: Diagnosis and Treatment of Neuroendocrine Tumors within a Multi-Institutional Collaboration in the Region of Antwerp-Waasland in Belgium
Introduction: Centralizing cancer services is one way to improve global outcome for cancer patients but brings along that patients must be motivated to travel and that doctors of local hospitals get deprived of the diagnostic and treatment skills. The alternative way is to centrally coordinate cancer services across different hospitals. In this scenario, local multidisciplinary teams refer all patients to be discussed among cancer specialists. This continuous feed-back system also creates the opportunity to propose additional more specific and sensitive examinations for individual patients which would introduce the end of local substandard treatment.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Marc Peeters
#2070 The Impact of NETwerk on the Multidisciplinary Tumor Boards
Introduction: Since 2016, nine hospitals from the Belgian region Antwerp-Waasland collaborate with the aim to optimize treatment of neuroendocrine tumor patients. NET cases are biweekly discussed by NET experts at a NET specific multidisciplinary tumor board (NET MDT). This collaboration (NETwerk) obtained a certificate of ENETS Center of Excellence in 2017.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Marc Peeters
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.